Janux Therapeutics (JANX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

JANX · Stock Price

USD 14.54-11.02 (-43.11%)

Market Cap: $863.8M

Historical price data

Market Cap: $863.8MPipeline: 3 drugsPatents: 3Founded: 2017Employees: 100-250HQ: San Diego, United States

Sector Ranking#22 in Immunotherapy / Immuno-Oncology #54 in Oncology (General)

Overview

Janux Therapeutics is on a mission to transform cancer and autoimmune disease treatment by developing precision-engineered, tumor-activated immunotherapies that maximize efficacy and safety. Founded in 2017, the company has rapidly advanced its proprietary TRACTr and TRACIr platforms, moving multiple programs into clinical development and securing high-value partnerships with Merck and Bristol Myers Squibb. Its strategy centers on solving the critical therapeutic index challenge in immuno-oncology, aiming to expand the utility of potent T-cell redirecting therapies into solid tumors, a vast and underserved market.

OncologyAutoimmune Diseases

Technology Platform

Proprietary TRACTr and TRACIr platforms engineer tumor-activated bispecific immunotherapies that are masked in circulation and selectively unmasked by proteases in the tumor microenvironment, aiming to maximize anti-tumor activity while minimizing systemic toxicity.

Pipeline

3

3 drugs in pipeline

Drug	Indication	Stage
JANX007 + Darolutamide	Prostate Cancer	Phase 1
JANX011	Autoimmune	Phase 1
JANX008	Non-Small Cell Lung Cancer	Phase 1

Funding History

2

Total raised:$256M

IPO$200MUndisclosedJul 28, 2021

Series A$56MRA Capital ManagementOct 15, 2020

Opportunities

The primary opportunity lies in successfully expanding the use of potent T-cell engagers into solid tumors, a multi-billion dollar market, by demonstrating a superior safety and efficacy profile.

Additionally, the ARM platform could unlock new treatment paradigms in autoimmune diseases.

Strategic partnerships provide validation, funding, and a path to accelerated development and commercialization.

Risk Factors

Key risks include clinical failure to demonstrate the platform's hypothesized therapeutic index advantage, intense competition from other next-generation T-cell engager approaches, potential biological limitations of tumor protease expression, and the need for future dilutive financing to advance the pipeline.

Competitive Landscape

Janux competes with established pharma and numerous biotechs in the T-cell engager space. Its primary differentiation is its protease-activated masking technology. Direct competitors with conditional activation platforms include CytomX Therapeutics and Amunix (now part of Takeda). Clinical data demonstrating a clear safety/efficacy advantage will be crucial for competitive differentiation.